6.09 USD
↘ 0.27 (4.25%)AT CLOSE (11:59 AM EDT)
Aclaris Therapeutics, Inc.
ACRSNASDAQ • USD
6.08
↘ 0.01 (0.16%)
POST MARKET (AS OF 07:34 PM EDT)
Post Market
AS OF 07:34 PM EDT
6.08
↘ 0.01 (0.16%)
Market: CLOSED
ACRS is currently priced at $6.08. ACRS shows a split signal: technical indicators suggest "Strong Buy" while underlying fundamentals indicate "Sell". Key drivers include a weak Piotroski F-Score of 2/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Furthermore, ACRS is currently richly valued, trading at a premium to sector peers across key valuation metrics.
Technical & fundamental data as of Aug 6, 2026.
Open?$6.34
High?$6.44
Low?$5.90
Prev. Close?$6.36
Volume?2.8M
Avg. Volume?2.2M
VWAP?$6.12
Rel. Volume?1.29x
Bid / Ask
Bid?$5.26 × 100
Ask?$7.31 × 100
Spread?$2.05
Midpoint?$6.29
Valuation & Ratios
Market Cap?888.3M
Shares Out?139.7M
Float?121.4M
Float %?86.9%
P/E Ratio?N/A
P/B Ratio?6.18
EPS?-$0.50
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Employees
73
Market Cap
888.3M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2015-10-07
Address
701 LEE ROAD
WAYNE, PA 19087
Phone: 484-324-7933
WAYNE, PA 19087
Phone: 484-324-7933
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?33
Momentum?80
Short Sent.?24
Piotroski F-Score?2/9Weak
Altman Z-Score?1.93Grey
Confidence?56%Low
Short InterestHigh
Short % of Float?11.01%High
Short Interest?13.4M
Days to Cover?6.9
Free Float121.4M
Avg Daily Volume1.9M
Settlement Date2026-07-15
Financial Health
Current Ratio?4.03Strong
Quick Ratio?4.03Strong
Cash Ratio?1.05Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?6.18FAIR▾
Peers100
S&P30
P/S?106.16HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-11.0CHEAP▾
S&P97
EV/Sales?102.74HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-48.5%WEAK▾
S&P3
ROA?-35.1%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-51986000
Enterprise Value?$859.6M
Fundamentals ratios updated end of day